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Abstract 
This mini systematic review seeks to analyse the available literature and determine if a 
4% articaine solution poses a greater risk of inferior alveolar and/or lingual nerve 
damage compared to that of 2% lidocaine when administered for an inferior alveolar 
nerve block. 
After a mini systematic review search of the published literature, seven suitable studies 
were identified, one double blind random controlled trial (DBRCT) and six retrospective 
cohort studies.  
The DBRCT and 2 of the cohort studies concluded that 4% articaine poses no greater 
risk of nerve damage. 
The remaining 4 cohort studies suggested that caution should be exhibited when using 
a 4% local anaesthetic solution rather than a 2% solution. However, these studies also 
concluded that no evidence exists to explain the reasons for their results. 
The included articles present no conclusive evidence to suggest that 4% articaine 
causes more nerve damage than 2% lidocaine although some authors advise caution 
when using this agent.  
All studies conclude that further quality research is required and it is therefore 
suggested that dental practitioners exhibit caution when choosing to use 4% articaine in 
an inferior alveolar nerve block until further scientific research has been performed 
 
 
 
Introduction 
Since 1949, lidocaine has been recognised as the “gold standard” of local anaesthetic 
agents.1 However, the desire to develop fast acting agents with a short half-life that also 
produce profound anaesthesia has led to the development of other alternatives. One 
example is articaine, initially synthesised in 1969 and used for the first time in clinical 
dental practice in Germany in 1976.  
The reason for articaine’s popularity appears to be due to its efficacy. Numerous studies 
have shown that articaine produces a more profound anaesthesia than that of 
lidocaine.2,3,4,5,6,7,8  
Lidocaine is an amide compound, based on a benzene ring structure (C6H6). Articaine, 
in contrast, possesses a thiophene ring (C4H4S), providing greater lipid solubility and an 
increased potency as a greater volume of an administered dose can enter the target 
neurons. Articaine’s lipid solubility has been quoted at over 4 times greater than that of 
lidocaine.9The same study confirmed that the onset of anaesthesia was achieved in 7.4 
mins with articaine as opposed to 8.7 mins with lidocaine.9 It has also been suggested 
that articaine provides a longer duration of anaesthesia due to its protein binding 
characteristics.10,11 
With these attributes, it is perhaps not surprising that many studies have concluded that 
articaine is more efficient at producing profound anaesthesia than lidocaine.6,12,13,14,15 
These papers include studies of both infiltration and nerve block anaesthesia. Other 
authors concluded that articaine has a faster onset than lidocaine11, and a meta-
analysis has proved that articaine is 1.6 – 3.5 times more potent than lidocaine.2  
Several studies have concluded that articaine should be recommended for use over 
lidocaine.2,6,12,16 In 2007, Robertson et al concluded that both the speed of onset and 
the anaesthetic efficacy of articaine were superior to those of lidocaine when 
administered via a buccal infiltration technique in the posterior molar region.14  
Another important attribute of a local anaesthetic agent is that of safety and this is 
perhaps where articaine compares less favourably. Since its introduction, several 
articles have been published warning of possible nerve damage when articaine is 
administered in an inferior alveolar nerve block (IANB).17,18 These articles indicate a risk 
of causing temporary or permanent paraesthesia of the inferior alveolar nerve (IAN) but 
evidence also exists contradicting these claims.3,19,20 
It appears, therefore, that the dental profession faces a dilemma. Should the more 
efficient agent be used to achieve faster, more profound anaesthesia or should the 
profession be wary of an agent that may have the potential to induce nerve damage? 
A mini systematic review of the literature was performed by a single researcher with 
one, clearly focused question21. The results of the study will hopefully provide advice to 
the dental profession, ensuring the continued provision of safe and effective local 
anaesthesia. 
 
 
 
 Methodology 
The Scottish Intercollegiate Guidelines Network (SIGN) presents eight levels of 
evidence-based research. The SIGN tool was used in this study according to the criteria 
set out in Table 1.22  
The development of the research question was aided using the PICOS method23, as 
described in Table 2. 
Inclusion and exclusion criteria were applied to the literature search as outlined in 
Tables 3 and 4. 
Basic search terms and medical sub headings terms were developed and detailed in 
Tables 5 and 6. 
3 electronic databases were chosen to systematically search the available literature:  
1. Medline with Full Text. 
2. Dentistry and Oral Sciences Source. 
3. The Cochrane Library 
 
Quality Assessment of Studies 
To ensure that the random controlled trials included in the review were accurately 
assessed against the inclusion and exclusion criteria, the risk of bias tool as described 
in the Cochrane Handbook for Systemic Reviews of Intervention was applied.24 
For the selected cohort studies, a Methodology Index for Non Randomised Studies 
(MINORS) was applied25, as described in Table 8. 
A record sheet was developed, and each study was subsequently scored as directed by 
Slim and Nini et al 200325 as defined in Table 9. 
 
Data Extraction 
Specifically designed data extraction forms were developed, allowing uniform data to be 
extracted under the following headings; 
 Study design  
 Study objectives 
 Geographical origin of the study 
 Clinical setting for the study  
 Study funding 
 Study participants – sex, age, numbers 
 Type of anaesthetic agent used 
 Study outcome – methods of recording and reporting nerve damage 
 Comparison made between “expected” and “observed” outcomes 
 Follow up periods 
 Attrition bias 
 Data analysis of outcomes 
 
 Results 
Data extraction and results of the mini systematic review are detailed in tables 10 – 18. 
 
 
Discussion 
 
Malamed and Gagnon’s study of 1325 participants enabled a statistical analysis of the 
results which indicated that the incidence of nerve damage was the same (1%) whether 
4% articaine or 2% lidocaine was used as the LA agent. Indeed, this DBRCT concluded 
that articaine is a “safe and effective” local anaesthetic agent.19 
Both studies conducted by Pogrel20,26, concluded that the incidence of nerve damage 
following the use of 4% articaine was in proportion to its market share. 
However, 3 of the studies indicated that the use of 4% articaine elicited more adverse 
outcomes than would be expected when compared to the agent’s market share.17,27,28 
 
Limitations and Characteristics of Included Studies 
 
Several methodological inconsistencies exist throughout the included studies, making a 
direct comparison between the chosen articles difficult. 
When performing a study comparing 2 pharmaceutical agents, a true comparison can 
only be achieved with the knowledge of the relative use of the 2 drugs within the studied 
population. 
Haas and Lennon17, Gaffen and Haas28 and Garisto, Gaffen et al27 all used the “null 
hypothesis” developed by Ronald Fisher.29  
However, the other included studies failed to indicate any comparison between 
expected and observed outcome events. 
The creation of a “barb” on the tip of the needle resulting from contact with the bone, 
may also be a factor in the traumatic damage to both the IAN and LN. However, 
whether or not this event occurred during any of the IANBs included in the studies, the 
resultant mechanical damage would be the same for both LA solutions.  
Of the 7 included papers, only one involves a DBRCT, 3 involve voluntary reporting of 
nerve damage and the remaining 3 articles elicit their information from patients who 
have been referred to a specialist centre for the specific reason that they are 
experiencing some degree of nerve damage. This clearly results in a considerable 
degree of reporting bias.  
With incidences of nerve damage ranging from 1: 27,000 to 1: 785,00017,30, it is clear 
that this study’s outcome is extremely rare. To obtain statistically significant results in a 
DBRCT would require a clinical trial on a very large scale. This could explain the 
existence of only one such study since 1976.19 
Both Hillerup and Jensen18 and Garisto and Gaffen27 make reference to the possibility 
of reporting bias in their papers and Gaffen and Haas28 admit that “reported incidence 
numbers should be viewed cautiously”. In his 2007 paper, Pogrel26 states that he 
estimates that his study represents approximately 10% of all cases of nerve damage in 
the given population per year. However, reporting bias for patients referred to a 
specialist centre would be the same for both LA solutions. 
The only study that included a detailed physical examination of the patient was that of 
Hillerup and Jensen18 using a “standardised test of neurosensory functions” by a single 
operator to determine the presence and extent of any reported nerve damage.31,32 The 
remaining included studies merely noted the incidence of “reported” nerve damage.  
Pogrel’s studies20,26, using data from a specialist centre and Garisto and Gaffen’s 
paper27 all failed to accurately examine the patient, relying instead on the patient’s own 
descriptions and a log of reported cases to AERS. Pogrel’s description of the patient 
“examination” lacks sufficient detail to allow exclusion of detection bias. 
The description of the reporting of an “electric shock” during the administration of the LA 
created notable discussion among the included authors. Four of the included papers 
noted the reporting of this phenomenon17,18,27,28 and all included these reports in their 
results as a “nerve injury”. The remaining 3 papers failed to mention this possible 
event.19,20,26 
Interestingly, Hillerup and Jensen state that “electric shock per se is probably of minor 
relevance for the aetiology of injection injuries”.18 However, they then go on to question 
the cause of nerve injury, admitting that it is unknown as to whether the nerve is 
damaged via neurotoxicity or mechanically, via intra-fascicular injection.  
Many authors are now advocating the use of 4% articaine in infiltration anaesthesia as 
an alternative to block anaesthesia due to the increased efficacy of this agent.33,34,35,36 
The evidence presented in these studies indicates a clear efficacy advantage when 
using 4% articaine as a buccal infiltration compared to 2% lidocaine in an IANB. One 
author has even suggested that the IANB may now be an unnecessary procedure.37 
 
Concentration of the LA agent 
Three of the chosen papers postulate that it may be the fact that, because articaine is 
administered in a 4% solution, it is the concentration of the LA solution rather than the 
actual pharmacology of the agent that causes damage to the nerve.17,27,28 This 
suggestion would appear to be confirmed by another study on rat sciatic nerves, which 
concluded that significantly more neurotoxic injuries were observed following the direct 
injection into the nerve of a 4% articaine solution compared to that of a 2% solution.38  
In a recent in-vitro study, articaine proved to be less neurotoxic than lidocaine, 
mepivacaine and prilocaine.39 Indeed, previous studies have concluded that no scientific 
evidence exists to confirm the suggestion that articaine causes increased paraesthesia 
and, to date, no causal relationship has been exhibited between an anaesthetic agent’s 
concentration and neurological damage.40,41   
 
 
 
Implications for Clinical Research 
This mini systematic review confirms that controversy still exists over the safety of 4% 
articaine and 1:100,000 adrenaline as a dental local anaesthetic agent.  
The authors of all the included papers admit that, due to the extremely rare occurrence 
of the outcome, a carefully performed, high quality DBRCT would have to involve such 
vast numbers of participants that, logistically, such a study would pose certain 
problems. 
It is generally accepted that 4% articaine exhibits greater lipid solubility, faster onset and 
increased duration of anaesthesia, more profound anaesthesia and reduced toxicity 
than those of its counterpart, 2% lidocaine. With these favourable attributes, 4% 
articaine does indeed offer superior properties over 2% lidocaine but would a 2% 
articaine solution offer the same advantages? 
Further research is required into the efficacy and safety of a 2% articaine solution. 
Indeed, a study in 2006 proved that the 4% articaine solution was not superior in its 
anaesthetic effect compared to 2% and 3% solutions of the same agent.42 
 
Implications for General Dental Practice 
The highest level of evidence available to this study was that of Malamed and Gagnon’s 
DBRCT in 2001.19 Although spread over 27 sites in 2 countries, this trial unfortunately 
exhibited several potential areas of bias. It did, however, conclude that there was no 
evidence to suggest that 4% articaine posed a greater risk of nerve damage than 2% 
lidocaine and that the use of 4% articaine in general dental practice can therefore be 
deemed safe and efficient. 
3 further papers, not included in this study, also concluded that no conclusive evidence 
exists to suggest that 4% articaine poses a greater risk of nerve damage compared to 
other LA agents.3,10,12  
 
Conclusion 
This mini systematic review of the literature has highlighted the fact that further research 
is required to determine the relative risks of using 4% articaine compared to 2% 
lidocaine in IANB’s.  
Clearly, the use of 4% articaine is becoming increasingly popular as a means of 
achieving successful dental anaesthesia and, if current trends continue, this agent may 
become the number one anaesthetic of choice in the future. This steady increase in 
popularity is likely to be due to the proven efficacy of this LA agent, benefiting both the 
patient and the operator. Indeed, the incidence of inferior alveolar nerve damage may 
reduce in the future as more evidence emerges to support infiltration anaesthesia. 
With this in mind and, considering the contradictory evidence presented in this study, it 
is suggested that, until factual evidence becomes available, dental practitioners should 
consider all the potential risks and benefits of a particular LA agent prior to its 
administration. 
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 Appendices 
Glossary of Abbreviations 
AERS: Adverse Event Reporting System 
DBRCT: Double Blind Random Controlled Trial  
IAN: Inferior Alveolar Nerve 
IANB: Inferior Alveolar Nerve Block 
LA: Local Anaesthetic 
LN: Lingual Nerve 
MeSH: Medical Sub Headings 
MINORS: Methodological Index for Non-Randomised Studies 
PICOS: Population, Intervention, Comparator, Outcome, Studies 
PRISMA: Preferred Reporting Items for Systematic reviews and Meta-Analyses 
SIGN: Scottish Intercollegiate Guidelines Network 
UCSF: University of California, San Francisco 
 
 
 
Tables 
 
 
 
Table 1: The Hierarchy of Evidence. Adapted from the Scottish Intercollegiate 
Guidelines Network (SIGN).43 
 
 
 
 
Level of 
Evidence 
Description of Evidence 
1++ High quality meta-analysis, systematic reviews of RCT’s or very low risk of 
bias RCT’s 
1+ Well conducted meta-analysis, systematic reviews of RCT’s or very low 
risk of bias RCT’s 
1- Meta-analysis, systematic reviews of RCT’s or RCT’s with a high risk of 
bias 
2++ High quality systematic reviews of cohort or case-control studies or high 
quality cohort or case-control studies with a very low risk of confounding 
bias or chance and a high probability that the relationship is causal 
2+ Well conducted cohort or case-control studies with a low risk of 
confounding, bias or chance and a moderate probability that the 
relationship is causal 
2- Cohort or case-control studies with a high risk of confounding, bias or 
chance and a significant risk that the relationship is not causal 
3 Non-analytical studies. Case reports and case series 
4 Expert opinion 
 PICOS 
 
Search Strategy Application 
Population Patients receiving IANB’s with either 4% 
articaine hydrochloride + 1:100,000 
adrenaline or patients receiving IANB’s 
with 2% lidocaine + 1:100,000 adrenaline. 
Males and females. All ages 
                                                                                   
Intervention Studies involving the administration of an 
IANB with 4% articaine + 1:100,000  
adrenaline 
                                                   
Comparison Studies involving the administration of an 
IANB with 2% lidocaine +1:100,000 
adrenaline 
 
Outcome Post injection nerve damage indicated by 
prolonged temporary or permanent 
anaesthesia, paraesthesia or 
dysaesthesia in both the intervention and 
comparison groups. 
 
Studies Randomised controlled trials comparing 
4% articaine + 1:100,000 adrenaline + 
2% lidocaine + 1:100,000 adrenaline in 
IANB’s.  
Cohort studies investigating the use of 
4% articaine + 1:100,000 adrenaline as a 
dental local anaesthetic agent in IANB’s. 
  
 
Table 2: PICOS parameters applied to the study.  
 
 
 
 
 
 
Inclusion Criteria 
 
English language papers 
 
 
Papers published since 1976 
 
Human subjects only 
 
Male and female subjects  
 
Global participation 
 
Subjects of all ages 
 
Articles involving IANB anaesthesia  
 
LA agents, lidocaine and articaine only  
 
Inferior alveolar and/or lingual nerve 
damage 
 
  
Permanent and/or temporary nerve 
damage  
 
 
Suitable ethical approval obtained 
 
 
Random Controlled Trials   
 
Cohort Studies 
 
 
 
Reason for Inclusion 
 
No translation facility. Author only speaks 
English. 
 
Articaine’s first use in clinical dentistry 
 
Relevant to general dental practice 
 
Maximum number of participants 
 
Maximum number of participants 
 
Maximum number of participants 
 
Specific to study question 
 
Specific to study question 
 
Anatomical possibility of damage to either 
nerve during the administration of an 
IANB. 
 
Both indicators of nerve damage 
 
 
 
Ethical and moral issues relating to 
research 
 
Good quality evidence 
 
Large number of subjects 
 
 
Table 3: Search Inclusion Criteria 
 
 
 
Exclusion Criteria 
 
Articles describing only infiltration 
anaesthesia 
 
 
Articles describing the use of anaesthetic 
agents other than articaine or lignocaine 
 
 
Studies investigating the use of articaine 
for “surgical dentistry” 
 
Studies investigating the use of articaine 
for removal of lower third molars and 
placement of mandibular implants 
 
  
“Sponsored” articles, unless a conflict of 
interest is declared 
 
Case studies 
 
Letters to editors 
 
Reason for Exclusion 
 
Administration of a nerve block is 
postulated as a cause of nerve damage 
 
 
Other anaesthetic agents not widely used 
in general dental practice 
 
 
Possible surgical cause of nerve damage 
 
 
Both recognised causes of possible 
inferior alveolar and lingual nerve 
paraesthesia 
 
 
Author bias 
 
 
Poor quality evidence 
 
Personal opinions 
Table 4: Search Exclusion Criteria 
 
 
 
 
Table 5. Basic Search Terms 
Table 5. Basic Search Terms 
 
Table 6. Medical Sub Headings Terms (MeSH Terms) 
Articaine, dental anaesthesia, nerve injury 
 
articaine, carticaine, septanest, ultracaine, septocaine, dental anaesthesia, 
lignocaine, lidocaine, xylocaine, paraesthesia, paresthesia, anaesthesia, anesthesia, 
dysaesthesia, dysesthesia, trigeminal nerve injuries, damage, injury, inferior alveolar 
nerve, inferior dental nerve, mandibular nerve, lingual nerve 
 
  
Table 7: Search Strategy 18/11/16 
 
 
 
Search No. Search Term 
  
S1 (MM "Carticaine") 
S2 septanest 
S3 articaine 
S4 ultracaine 
S5 septocaine 
S6 (MM "Anesthesia, Dental+") 
S7 lignocaine 
S8 lidocaine 
S9 xylocaine 
S10 S1 OR S2 OR S3 OR S4 OR S5 OR S6 
S11 S7 OR S8 OR S9 
S12 paraesthesia 
S13 paresthesia 
S14 anaesthesia 
S15 anesthesia 
S16 dysaesthesia 
S17 dysesthesia 
S18 (MM "Trigeminal Nerve Injuries+") 
 
S19 damage 
S20 injury 
S21 inferior alveolar nerve 
S22 inferior dental nerve 
S23 mandibular nerve 
S24 lingual nerve 
S25 S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 
OR S20 
S26 S21 OR S22 OR S23 OR S24 
S27 S10 AND S11 AND S25 AND S26 
 Table 8: Methodology Index for Non Randomised Studies (MINORS).25 
 
Item Score Reason 
0 Not reported 
1 Reported but inadequate 
2 Reported and adequate 
 
Table 9. MINORS criteria scores. 
 
Methodological Items for Non-
Randomised Studies 
Item Description 
Clearly stated aim Relevant and precise study question, 
relating to available literature 
Inclusion of consecutive patients All eligible participants included in study 
Prospective collection of data Data collected as per guidelines 
established prior to study commencement 
Endpoints appropriate to study aim Clear, quantifiable outcome addressing 
study question 
Unbiased endpoint Blind assessment of endpoint 
Review period appropriate to aim Review period sufficient to allow outcome 
occurrence and measurement 
Attrition bias less than 5% All patients should be reviewed 
Prospective calculation of study size Information regarding study population 
size necessary to achieve 95% 
confidence interval and level of statistical 
significance 
Additional Items for use in Comparative 
Studies 
Item Description 
Suitable control “Gold standard” as per available 
information 
Contemporary groups Groups studies during the same time 
period 
Baseline equivalent groups Group criteria similar at start point 
Statistical analysis Suitable statistics with confidence 
intervals or relative risk 
Table 10. Search Strategy and Results (performed on 30-12-16) 
 
Search No. Search Term Dentistry & Oral 
Science 
Medline Cochrane 
     
S1 (MM "Carticaine") 2 303 3 
S2 septanest 2 4 1 
S3 articaine 216 398 3 
S4 ultracaine 4 47 9 
S5 septocaine 6 3 1 
S6 (MM "Anesthesia, 
Dental+") 
1,277 5,827 9 
S7 lignocaine 332 2,405 11 
S8 lidocaine 561 25,426 47 
S9 xylocaine 306 713 1 
S10 S1 OR S2 OR S3 
OR S4 OR S5 OR 
S6 
1,429 6,139 9 
S11 S7 OR S8 OR S9 592 26,463 55 
S12 paraesthesia 117 1,134 195 
S13 paresthesia 31 7,415 50 
S14 anaesthesia 6,591 65,803 1078 
S15 anesthesia 6,591 200,202 334 
S16 dysaesthesia 24 265 23 
S17 dysesthesia 61 1278 13 
S18 (MM "Trigeminal 
Nerve Injuries+") 
 
84 833 13 
S19 damage 3,284 433,750 2,568 
S20 injury 9,260 549,161 2,570 
S21 inferior alveolar 
nerve 
1124 2,102 13 
S22 inferior dental 
nerve 
78 142 18 
S23 mandibular nerve 568 3,556 36 
S24 lingual nerve 269 1,298 18 
S25 S12 OR S13 OR 
S14 OR S15 OR 
S16 OR S17 OR 
S18 OR S19 OR 
S20 
18,767 1,145,705 4,497 
S26 S21 OR S22 OR 
S23 OR S24 
1,492 5281 55 
S27 S10 AND S11 AND 
S25 AND S26 
36 170 2 
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                Table 11: PRISMA diagram indicating selection/inclusion process 
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 Articles identified through database searching. 
Dentistry                    Medline           Cochrane 
& Oral Sciences                                    Library 
Source 
     36                               170                      2 
n = 208 
Duplicates removed 
n = 26 
Articles screened 
n = 182 
 
Excluded articles. 
Not human subjects                         n = 3 
Infiltration anaesthesia only           n = 19 
Agents other than 4% articaine      n = 26 
4% articaine used in surgical 
Procedure                                           n = 3 
Articles involving only lidocaine     n = 30 
Articles discussing efficacy only      n = 16 
Articles not discussing IDN               n = 8 
Articles not answering the 
research question                              n = 66 
                   
n = 171 
Relevant articles 
n = 11 
 
Hand searched 
additional articles 
n = 4 
Studies included in 
quantitative/qualitative synthesis 
n = 7 
Articles excluded as not primary 
research 
n = 8 
  
 
 
Table 12: Included Studies 
 
 
 
Title and Author(s) Year “SIGN” 
Level of 
Evidence 
Type of study 
A 21 Year Retrospective Study Of 
Reports Of Paresthesia Following 
Local Anesthetic Administration. 
Hass and Lennon17 
1995 2- Retrospective Cohort 
Retrospective Review Of Voluntary 
Reports Of Nonsurgical Paresthesia 
in Dentistry. 
Gaffen and Haas28 
2009 2- Retrospective Cohort 
Nerve Injury Caused By Mandibular 
Block Analgesia. 
Hillerup and Jenson18 
2006 2- Retrospective Cohort 
Permanent Nerve Damage From 
Inferior Alveolar Nerve Blocks – An 
Update to Include Articaine. 
Pogrel26 
2007 2- Retrospective Cohort 
Articaine Hydrochloride: a study of 
the safety of a new amide local 
anesthetic. 
Malamed, Gagnon et al19 
2001 1- Random Controlled Trials 
Occurrence of paresthesia after 
dental local anesthetic 
administration in the United States. 
Garisto, Gaffen et al27 
2010 2- Retrospective Cohort 
Permanent Nerve Damage From 
Inferior Alveolar Nerve Blocks: A 
Current Update. 
Pogrel20 
2012 2- Retrospective Cohort 
  
Article(s) 
 
Reason for Exclusion 
Aguiar, Chebroux et al.44 
Hung, Chang et al.45  
Potocnik, Tomsic et al.46  
Sisk.47 
Baroni, Franz-Montan et al.48 
Batista, Berto et al.49 
 
Incorrect Population. n = 6 
Studies on rats and cats. 
Studies using Cow–Gates and Akinosi IANB.  
Studies of mental and incisive nerve blocks. 
 
Chopra, Jindal et al.50  
Danielsson, Evers et al.51  
Rood.52 
Incorrect Intervention. n = 48 
Studies comparing Lidocaine, etidocaine and 
bupivacaine. 
 
Rood.52 Incorrect Comparator. n = 1 
5% lidocaine solution used in study. 
 
Ahmad, Ravikumar et al.53 
Kambalimath, Dolas et al.54  
Moorthy, Stassen.55  
Choi, Seo et al.56  
Al-Sandook, Al-Saraj.57  
 
Incorrect Outcome. n = 42 
Studies measuring articaine’s efficacy only. 
Studies detailing damage to nerves other than 
IAN and/or LN. 
 
Choi, Seo et al.56  
Wyman.58  
Pedlar.59 
 
Incorrect Studies. n = 8 
Case reports and letters to editors. 
 
Fowler, Reader.60  
Steinkruger, Nusstein et al.61  
Articles not answering study question. n = 66 
Studies comparing volume of anaesthetic agent 
and injection technique. 
 
 
Table 13. Examples of excluded studies 
 
 
 Table 14: MINORS Checklist for Included Studies 
 
Criteria Haas & 
Lennon17 
Gaffen 
& 
Haas28 
Hillerup 
& 
Jenson18 
Pogrel26 Malamed 
& 
Gagnon19 
Garisto 
& 
Gaffen27 
Pogrel20 
Clearly stated 
aim 
2 2 2 2 2 2 2 
Inclusion of 
consecutive 
patients 
1 2 2 2 1 2 2 
Prospective 
collection of 
data 
2 2 2 2 2 2 2 
Endpoint 
appropriate to 
study 
2 2 2 2 2 2 2 
Unbiased 
assessment 
of endpoint 
1 1 1 1 2 1 1 
Appropriate 
follow up 
period 
0 1 2 2 1 1 2 
Loss to follow 
up less than 
5% 
1 0 0 0 0 0 0 
Prospective 
calculation of 
study size 
0 0 0 0 0 0 0 
Adequate 
control group 
NA NA NA NA 2 NA NA 
Contemporary 
groups 
NA NA NA NA 2 NA NA 
Baseline 
equivalence 
groups 
NA NA NA NA 2 NA NA 
Adequate 
statistical 
analysis 
NA NA NA NA 1 NA NA 
Total Score 9 10 11 11 17 10 11 
Bias Malamed and Gagnon19 
Random sequence generation (selection 
bias) 
Low risk “There were no statistically 
significant differences in the studies 
between the articaine and lidocaine 
treatment groups with respect to age, 
sex, weight, race distribution or the 
proportion of subjects undergoing simple 
or complex procedures” 
Allocation concealment (selection bias) Unclear risk. Not mentioned in 
methodology 
Blinding of outcome assessment 
(detection bias) 
Unclear risk. “Randomised, double-
blind…” mentioned in methodology but no 
other details 
Participant awareness (performance bias) Unclear risk. Not mentioned in 
methodology 
Incomplete outcome data (attrition bias) High risk. No mention of attrition at 24 
hour and 7 day follow up interviews  
Sponsorship (funding bias) Low risk. “The manufacturer of the drug 
products used in the three 
trials…..providing materials and funding.” 
The same company manufactures both 
the intervention and comparator drugs. 
Selective reporting (reporting bias) Unclear risk. “The vast majority of these 
events are related by (telephone 
interviews with) patients and are alleged 
as opposed to confirmed.” 
Overall risk of bias Unclear risk. 
 
Table15: Risk of Assessment Bias (adapted from Higgins, Altman et al.24). 
 
 
 
  
Table 16a: Data Extraction 
 
Study Haas & Lennon17  Gaffen & Haas28 Hillerup & Jensen18 
Study publication 
date 
April 1995 October 2009 May 2006 
Study design Retrospective 
Cohort 
Retrospective 
Cohort 
Retrospective Cohort 
Study objectives Prolonged 
paraesthesia 
following LA in 
dentistry 
Prolonged 
paraesthesia 
following LA in 
dentistry 
Prolonged paraesthesia 
following LA in dentistry 
Geographical origin Ontario, Canada Ontario, Canada Denmark 
Study setting Not Stated Not stated “All dental practitioners” 
Study funding Not stated “no declared 
financial 
interests” 
Not Stated 
Eligible study 
participants 
143, male and 
female, all ages 
172, male and 
female, 11-80 
years 
52, male and female, 24 – 
81 years 
LA agents used Lidocaine, 
articaine, 
prilocaine, 
mepivacaine, 
bupivacaine 
Lidocaine, 
articaine, 
prilocaine, 
mepivacaine, 
bupivacaine 
Lidocaine, articaine, 
prilocaine, mepivacaine 
Outcome reporting 
and recording 
Voluntary reports 
to PLP 
Voluntary reports 
to PLP 
Telephone call to GDP. 
Type and volume of LA 
used. Electric shock 
experienced? 
Written questionnaires and 
patient interviews 
Comparison made 
between 
“expected” and 
“observed” 
outcomes 
Yes Yes No 
Study period 21 years, 1973 - 
1993 
10 years, 1999 - 
2008 
8 years, 1997 – June 2004 
Attrition bias Not stated Not stated 30 patients (58%) lost to 
follow up after 12 months 
Data analysis of 
outcomes 
Chi – square 
analysis 
Chi – square 
analysis 
Chi – square analysis 
Ethical approval Not stated Stated Obtained Not stated 
 Study Pogrel26  Malamed, 
Gagnon et al19 
Garisto, Gaffen 
et al27 
Pogrel20 
Study 
publication date 
April 2007 February 2001 July 2010 October 2012 
Study design Retrospective 
Cohort 
3 Double Blind 
Random 
Controlled 
Trials 
Retrospective 
Cohort 
Retrospective 
Cohort 
Study objectives Prolonged 
IAN/LN 
paraesthesia 
following LA in 
dentistry 
Direct 
comparison of 
efficacy and 
safety between 
4% articaine 
and 2% 
lidocaine  
Record 
incidence of 
nerve damage 
after LA in 
dentistry 
Prolonged 
IAN/LN 
paraesthesia 
following LA 
in dentistry 
Geographical 
origin 
Maxillo Facial 
Dept, UCSF, 
USA 
27 sites, 8 in 
the UK and 19 
in the USA 
USA Maxillo Facial 
Dept, UCSF, 
USA 
Study setting Primary and 
secondary 
dental care 
No stated Voluntary 
reports to 
FDA’s AERS 
Primary and 
secondary 
dental care 
Study funding Not stated “Materials and 
funding” 
provided by 
manufacturers 
of the LA 
agents 
No 
“disclosures” 
reported by 
authors 
Not stated 
Eligible study 
participants 
57, sex and 
ages not stated 
1325, male and 
female, aged 4 
– 80 years 
226, male and 
female, 15 - 78 
years 
38, sex and 
ages not 
stated 
LA agents used Lidocaine, 
articaine, 
prilocaine, 
mepivacaine, 
bupivacaine 
2% Lidocaine, 
4% articaine, 
Lidocaine, 
articaine, 
prilocaine, 
mepivacaine, 
bupivacaine 
Lidocaine, 
articaine, 
prilocaine, 
carbocaine 
Outcome 
reporting and 
recording 
Examination of 
patient at 
UCSF. Details 
of examination 
not stated  
Interviews and 
telephone calls 
to the patients. 
No further 
details of 
examination 
Voluntary 
reports to 
FDA’s AERS. 
Duration of 
paraesthesia 
noted 
 
Examination 
of patient at 
UCSF. 
Details of 
examination 
not stated  
Comparison 
made between 
“expected” and 
“observed” 
outcomes 
Yes No Yes Yes 
Study period 3 years. 
01/01/03 – 
31/12/05 
Not stated 11 years, 
November 
1997 – August 
2008 
6 years, 
01/01/06 – 
31/12/11 
Attrition bias Not Stated 3 patients lost 
to follow up 
(0.23%) 
Not stated Not stated 
Data analysis of 
outcomes 
Narrative Narrative Descriptive 
statistical 
analysis 
Narrative 
Ethical approval Not stated  Stated as 
obtained in UK 
and USA 
Stated as 
obtained and 
approved by 
University of 
Toronto 
Not stated 
 
Table 16b: Data Extraction 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study Design Number of 
eligible 
participants 
with 
outcome* 
Number of 
participants 
with outcome 
following 
intervention 
(articaine) 
Number of 
participants 
with outcome 
following 
comparison 
(lidocaine) 
Reported 
Outcomes  
Haas & 
Lennon17 
Retrospective
Cohort 
143* 50 5 Paraesthesia 
following the 
injection of 
LA in non-
surgical 
dentsistry 
Gaffen & 
Haas28 
Retrospective
Cohort 
172* 109 23 Non-surgical 
paraesthesia 
Hillerup & 
Jensen18 
Retrospective
Cohort 
52* 29 10 Non-surgical 
IAN or LN 
injury 
following a 
unilateral 
IANB 
Pogrel26 Retrospective
Cohort 
57* 17 20 Damage to 
IAN or LN 
following an 
IANB 
Malamed, 
Gagnon et 
al19 
Double Blind 
Random 
Controlled 
Trial 
13 8 5 “numbness or 
tingling 4 – 8 
days after the 
procedure” 
Garisto, 
Gaffen et 
al27 
Retrospective
Cohort 
226* 116 11 Oral 
paraesthesia 
following 
dental 
treatment 
Pogrel20 Retrospective
Cohort 
38* 14 10 Damage to 
IAN or LN 
following an  
IANB 
 
 
Table 17: Summary of Outcome Characteristics of Included Studies 
 
* In all the included studies except Malamed, Gagnon et al, agents other than articaine 
and lidocaine were also studied and included in the study results. The inclusion of 
prilocaine, mepivacaine, bupivacaine and carbocaine explains the discrepancy between 
the sum of the intervention (articaine) and comparison (lidocaine) participants and that 
of the number of eligible participants in each study. 
 
Table 18a: Summary of Study Findings 
Study Haas & Lennon17 Gaffen & Haas28 Hillerup & Jensen18 
Number of incidences 
of IAN damage with 
articaine 
Not reported Not reported 5  
Number of incidences 
of LN damage with 
articaine 
Not reported Not reported 24  
Number of incidences 
of IAN and/or LN 
damage with articaine 
50 (33.6%) 109 (59.9%) 29 (54%) 
Number of incidences 
of IAN damage with 
lidocaine 
Not reported Not reported 3 
Number of incidences 
of LN damage with 
lidocaine 
Not reported Not reported 7 
Number of incidences 
of IAN and/or LN 
damage with lidocaine 
5 (3.4%) 23 (12.6%) 10 (19%) 
Expected frequency of 
IAN and/or LN damage 
with articaine*   
5.3 26.5 Not reported 
Observed frequency of 
IAN and/or LN damage 
with articaine  
10 42 Not reported 
Expected frequency of 
IAN and/or LN damage 
with lidocaine*  
3.7 23.8 Not reported 
Observed frequency of 
IAN and/or LN damage 
with lidocaine  
0 6 Not reported 
 * Expected frequencies calculated using the “null hypothesis”.29 
 
Table 18b: Summary of Study Findings 
 
 
Study Pogrel26 Malamed, 
Gagnon et al19 
Garisto, Gaffen 
et al27 
Pogrel20 
Number of incidences 
of IAN damage with 
articaine 
Not reported Not reported Not reported Not reported 
Number of incidences 
of LN damage with 
articaine 
Not reported Not reported Not reported Not reported 
Number of incidences 
of IAN and/or LN 
damage with articaine 
17 (29.8%) 8 (1%) 116 (51.3%) 14 (37%) 
Number of incidences 
of IAN damage with 
lidocaine 
Not reported Not reported Not reported Not reported 
Number of incidences 
of LN damage with 
lidocaine 
Not reported Not reported Not reported Not reported 
Number of incidences 
of IAN and/or LN 
damage with lidocaine 
20 (35%) 5 (1%) 11 (4.9%) 10 (26%) 
Expected frequency 
of IAN and/or LN 
damage with 
articaine*   
Not reported Not reported 32 Not reported 
Observed frequency 
of IAN and/or LN 
damage with articaine  
Not reported Not reported 116 Not reported 
Expected frequency 
of IAN and/or LN 
damage with 
lidocaine*  
Not reported Not reported 130 Not reported 
Observed frequency 
of IAN and/or LN 
damage with lidocaine  
Not reported Not reported 10 Not reported 
 
